Know the risks of specialty carve-out
CVS Health leaders share key cost considerations for carving out specialty benefits
Specialty carve-out savings seem too good to be true. Are they?
Payors seeking tighter management of specialty drugs and greater specialty savings won’t find them by carving out. The reality is quite different from the hype. A carved-out approach perpetuates fragmented specialty management – which can impact cost, jeopardize patient care and disrupt member experience.
Hear from Joshua Fredell, PharmD, Vice President and Head of PBM and Specialty Product Development, CVS Health, and Travis Tate, Vice President, PBM Product Development, Formulary and Trend, CVS Health. They share important considerations for evaluating niche vendors that promise dramatic savings.
